WallStSmart

Curanex Pharmaceuticals Inc Common Stock (CURX)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).

CURX

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 18.01

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 2.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CURX.

JNJSignificantly Overvalued (-84.0%)

Margin of Safety

-84.0%

Fair Value

$145.14

Current Price

$270.47

$125.33 premium

UndervaluedFair: $145.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CURX3 strengths · Avg: 9.7/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
18.0110/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

CURX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.53M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

JNJ4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-95.9%2/10

Earnings declined 95.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : CURX

The strongest argument for CURX centers on Price/Book, Altman Z-Score, Debt/Equity.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bear Case : CURX

The primary concerns for CURX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : JNJ

The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 43.0x leaves little room for execution misses.

Key Dynamics to Monitor

CURX profiles as a value stock while JNJ is a mature play — different risk/reward profiles.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JNJ scores higher overall (54/100 vs 23/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Curanex Pharmaceuticals Inc Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. The company is headquartered in Jericho, New York.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?